Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Leases (2022 - 2025)

Ovid Therapeutics' Leases history spans 4 years, with the latest figure at $11.6 million for Q4 2025.

  • For Q4 2025, Leases fell 9.28% year-over-year to $11.6 million; the TTM value through Dec 2025 reached $11.6 million, down 9.28%, while the annual FY2025 figure was $11.6 million, 9.28% down from the prior year.
  • Leases reached $11.6 million in Q4 2025 per OVID's latest filing, down from $11.9 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $15.7 million in Q1 2022 to a low of $11.6 million in Q4 2025.
  • Average Leases over 4 years is $13.7 million, with a median of $13.8 million recorded in 2023.
  • Peak YoY movement for Leases: decreased 6.51% in 2023, then dropped 9.28% in 2025.
  • A 4-year view of Leases shows it stood at $14.9 million in 2022, then decreased by 6.89% to $13.9 million in 2023, then dropped by 7.9% to $12.8 million in 2024, then fell by 9.28% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Leases are $11.6 million (Q4 2025), $11.9 million (Q3 2025), and $12.2 million (Q2 2025).